Figure 3From: The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trialsTime course of improvement – Emotional function: mean change from baseline in Migraine-Specific Questionnaire (MSQ) domain scores. *p < 0.001, †p = 0.024 versus placebo. EP = end point; LOCF = last observation carried forward; TPM = topiramate.Back to article page